LA JOLLA, CA—In the expanding frontier of immunology, a striking reality has gained renewed focus: diseases do not impact men and women identically. From asthma manifesting earlier in males but evolving more prevalently among females in later life, to neurodegenerative disorders like Parkinson’s disease predominantly affecting men while Alzheimer’s disease more commonly besets women, sex-based biological distinctions are pivotal in shaping health outcomes. Now, groundbreaking research from the La Jolla Institute for Immunology (LJI) is elucidating the molecular and cellular underpinnings that drive these divergent immune responses, shedding light on tissue-specific immunity modulated by sex chromosomes, hormones, and environmental factors.
The immune system’s complexity is, at its core, influenced by genetic sex—defined immunologically by the presence of XX chromosomes in females and XY chromosomes in males—a principle that governs not only reproductive function but also systemic immunity. Women, possessing two X chromosomes, inherently carry a dual set of immune-related genes, a redundancy that provides a broader genetic palette for immune cell functionality. This chromosomal advantage translates to amplified immune responses in females for genes expressed from both X copies, as some escape the usual silencing of one X chromosome, a phenomenon known as X chromosome “dosage.” However, this genetic richness is a double-edged sword, potentially predisposing women to higher incidences of autoimmune diseases such as lupus, Sjögren’s syndrome, and scleroderma, where the immune system erroneously targets the body’s own tissues.
Sex hormones—particularly estrogen and testosterone—integrate with genetic predispositions to modulate immune cell behavior dynamically. Immune cells express receptors capable of sensing these hormones and consequently adjust gene expression profiles. This hormone-driven regulation fine-tunes immune responses, contributing to functional differences in immune cell activity between sexes. For instance, estrogen can enhance the activation and proliferation of certain lymphocyte subsets, while testosterone tends to suppress inflammatory responses. This hormone-mediated gene regulation imbues similar immune cells from males and females with the capacity to execute distinct immunological functions, further diversifying tissue-specific immunity.
Adding yet another layer of complexity is the mosaicism inherent in female tissues. Unlike the uniform expression in males, female cells variably activate one of their two X chromosomes in different cells and tissues, resulting in a heterogeneous immune landscape within the same individual. This cellular mosaicism generates a broad spectrum of immune cell phenotypes, enabling a multifaceted defense against pathogens. Indeed, epidemiological data underscore that females often mount more robust responses to infections such as SARS-CoV-2, effectively clearing viral challenges more efficiently than males. Such diversified immunity likely evolved as a survival advantage, though it carries associated costs.
The ramifications of these sex differences extend far beyond infectious disease, influencing the pathology of chronic immune-mediated conditions. The heightened immune vigilance in females, orchestrated by genetic and hormonal factors, can tilt the immune balance towards autoimmunity. The increased expression of immune-related genes from the X chromosome likely escalates antigen presentation and immune activation thresholds, thereby increasing the risk of breaking tolerance and triggering self-reactive immune responses. This insight reframes our understanding of autoimmune pathogenesis, shifting attention toward mechanisms unique to sex chromosome biology.
Research led by LJI scientists, including Professor Erica Ollmann Saphire and Associate Professor Sonia Sharma, is pioneering new avenues to integrate these findings into clinical frameworks, particularly in oncology. Immunotherapy, a rapidly advancing therapeutic frontier, harnesses the patient’s immune system to target cancer cells. Such treatments, however, exhibit variable efficacy between men and women, mirroring inherent immunological differences. By dissecting how sex-based immune variations influence tumor immunosurveillance and therapeutic responsiveness, researchers aim to develop precision immunotherapies tailored to the patient’s biological sex, thereby optimizing outcomes in cancer care.
Environmental factors further complicate the immune landscape. Nutrition, chemical exposures, and the microbiomes of the skin and gut also differ by sex, contributing additional variables that shape immune function tissue-specifically. For instance, variances in microbial communities between males and females influence local immune responses and metabolic pathways, impacting both disease susceptibility and progression. These multifactorial interactions underscore the necessity of comprehensive models that account for genetic, hormonal, and environmental determinants of immunity.
The implications of these discoveries reach well beyond academic intrigue, calling for a paradigm shift in medical practice and research design. Historically, many clinical studies have underrepresented women or neglected sex as a biological variable, limiting the efficacy and safety of treatments across populations. The emerging evidence advocates for incorporating sex-specific analyses into all stages of biomedical research and clinical trials. This approach extends to drug development, vaccine design, and public health strategies, ultimately moving toward truly personalized medicine.
LJI’s Center for Sex-Based Differences in the Immune System is spearheading this transformative effort, facilitating interdisciplinary collaborations that leverage immunology, genomics, endocrinology, and bioinformatics. Such synergy is critical to translate foundational research into tangible health benefits. Researchers emphasize that understanding sex differences at the tissue and cellular level is fundamental to decoding disease mechanisms and enhancing therapeutic precision.
The future landscape of immunology promises to unravel even more intricate networks where sex chromosomes and hormones intricately orchestrate immunity in a tissue-dependent manner. This knowledge, coupled with advanced technologies like single-cell sequencing and spatial transcriptomics, will map the immune mosaic at unprecedented resolution. Ultimately, these insights hold the potential to revolutionize the prevention, diagnosis, and treatment of myriad diseases that disproportionately affect men or women.
As this research field accelerates, it becomes increasingly evident that incorporating sex as a fundamental biological variable moves beyond equity; it is a scientific imperative. The nuanced understanding of sex-specific immunity will not only deepen our grasp of human biology but also foster innovations that enhance health outcomes for all, embodying the promise of precision medicine for a future where sex-based differences inform every therapeutic decision.
Subject of Research: Not applicable
Article Title: Sex differences in tissue-specific immunity and immunology
News Publication Date: 7-Aug-2025
Web References:
https://www.science.org/doi/10.1126/science.adx4381
References:
Ollmann Saphire, E., Sharma, S., Gibbons, A., et al. “Sex differences in tissue-specific immunity and immunology.” Science (2025). DOI: 10.1126/science.adx4381
Keywords: Personalized medicine; Clinical medicine; Human health; Diseases and disorders; Immune disorders; Autoimmune disorders; Infectious diseases; Cancer immunology; Cancer immunotherapy; Immunosurveillance
